首页> 外文期刊>Modern Pathology >Prognostic value of mitotic checkpoint protein BUB3, cyclin B1, and pituitary tumor-transforming 1 expression in prostate cancer
【24h】

Prognostic value of mitotic checkpoint protein BUB3, cyclin B1, and pituitary tumor-transforming 1 expression in prostate cancer

机译:有丝分裂检查点蛋白Bub3,细胞周期蛋白B1和垂体肿瘤转化1表达前列腺癌的预后价值

获取原文
           

摘要

The mitotic checkpoint protein BUB3, cyclin B1 (CCNB1) and pituitary tumor-transforming 1 (PTTG1) regulates cell division, and are sparsely studied in prostate cancer. Deregulation of these genes can lead to genomic instability, a characteristic of more aggressive tumors. We aimed to determine the expression levels of BUB3, CCNB1, and PTTG1 as potential prognostic markers of recurrence after radical prostatectomy. Protein levels were determined by immunohistochemistry on three formalin-fixed paraffin-embedded tissue sections from each of the 253 patients treated with radical prostatectomy. Immunohistochemistry scores were obtained by automated image analysis for CCNB1 and PTTG1. Recurrence, defined as locoregional recurrence, distant metastasis or death from prostate cancer, was used as endpoint for survival analysis. Tumors having both positive and negative tumor areas for cytoplasmic BUB3 (30%), CCNB1 (28%), or PTTG1 (35%) were considered heterogeneous. Patients with 1 positive tumor area had significantly increased risk of disease recurrence in univariable analysis compared with patients where all tumor areas were negative for cytoplasmic BUB3 (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.41-3.36), CCNB1 (HR = 2.98, 95% CI 1.93-4.61) and PTTG1 (HR = 1.91, 95% CI 1.23-2.97). Combining the scores of cytoplasmic BUB3 and CCNB1 improved risk stratification when integrated with the Cancer of the Prostate Risk Assessment post-Surgical (CAPRA-S) score (difference in concordance index = 0.024, 95% CI 0.001-0.05). In analysis of multiple tumor areas, prognostic value was observed for cytoplasmic BUB3, CCNB1, and PTTG1.
机译:有丝分裂检查点蛋白Bub3,细胞周期蛋白B1(CCNB1)和垂体肿瘤转化1(PTTG1)调节细胞分裂,并在前列腺癌中稀疏地研究。对这些基因的放松管制可导致基因组不稳定性,具有更具侵袭性肿瘤的特征。我们的目标是确定Bub3,CCNB1和PTTG1的表达水平,作为自由基前列腺切除术后复发的潜在预后标志物。通过免疫组织化学在三种福尔马林固定的石蜡包埋的组织切片中由来自自由基前列腺切除术治疗的253名患者中的每种蛋白质水平测定的蛋白质水平。通过CCNB1和PTTG1的自动图像分析获得免疫组织化学分数。复发,定义为型患者复发,从前列腺癌的远处转移或死亡,用作生存分析的终点。具有细胞质Bub3(30%),CCNB1(28%)或PTTG1(35%)的阳性和阴性肿瘤区域的肿瘤被认为是非均相的。与所有肿瘤区域对细胞质Bub3的患者相比,1例阳性肿瘤区域的疾病复发风险显着增加了疾病复发的风险,与所有肿瘤区域为阴性的患者(危险比[HR] = 2.18,95%置信区间[CI] 1.41-3.36),CCNB1 (HR = 2.98,95%CI 1.93-4.61)和PTTG1(HR = 1.91,95%CI 1.23-2.97)。结合细胞质Bub3和CCNB1的分数改善风险分层时,随着手术前列腺危险评估(Capra-S)得分(一致性指数差异= 0.024,95%CI1-0.05)。在分析多个肿瘤区域时,对于细胞质Bub3,CCNB1和PTTG1,观察到预后值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号